MRNA Financials Tuesday, July 15, 2014 6:33:25 PM
Post# of 19
Posted On: 07/15/2014 6:33:26 PM
MRNA Financials Tuesday, July 15, 2014 6:33:25 PM
Marina Biotech, Inc.
Period Ending Dec 31, 2011 Dec 31, 2010
Total Revenue 2,236 2,460
Cost of Revenue - -
Gross Profit 2,236 2,460
Operating Expenses
Research and Development 11,438 18,105
Sales, General and Admin. 8,369 10,359
Non-Recurring Items 17,424 3,526
Other - -
Operating Income (34,995) (29,530)
Income From Continuing Operations
Add'l Income/Expense Items 6,714 4,604
Earnings Before Interest and Tax (28,281) (24,926)
Interest Expense - 2,827
Earnings Before Tax (28,281) (27,753)
Income Tax 1,143 -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (29,424) (27,753)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (29,424) (27,753)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (29,424) (27,753)
Marina Biotech, Inc.
Period Ending Dec 31, 2011 Dec 31, 2010
Total Revenue 2,236 2,460
Cost of Revenue - -
Gross Profit 2,236 2,460
Operating Expenses
Research and Development 11,438 18,105
Sales, General and Admin. 8,369 10,359
Non-Recurring Items 17,424 3,526
Other - -
Operating Income (34,995) (29,530)
Income From Continuing Operations
Add'l Income/Expense Items 6,714 4,604
Earnings Before Interest and Tax (28,281) (24,926)
Interest Expense - 2,827
Earnings Before Tax (28,281) (27,753)
Income Tax 1,143 -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (29,424) (27,753)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (29,424) (27,753)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (29,424) (27,753)
(0)
(0)Adhera Therapeutics Inc. (ATRX) Stock Research Links
Scroll down for more posts ▼